Cytosorbents earnings release, August 6, 2026

Cytosorbents Corp (CTSO) · Form 8-K, Item 2.02 · Filed · SEC filing

CytoSorbents

Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Highlighting

Four Independent Drivers of Shareholder Value

PRINCETON, N.J.,

August 6, 2026 — CytoSorbents Corporation

(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.

Second Quarter 2026 Financial Results

“Second quarter revenue performance was led by strong growth in our distributor and strategic partner territories, as well as direct sales outside of

Germany, but offset by a decline in sales in Germany attributed to a smaller, but more focused sales force. We are encouraged by the improved productivity and sales execution of this team and expect to add three to five new sales representatives through early 2027 to restore full country coverage,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “We are also pleased with the continued improvements in our operating execution in the quarter, including an increase in gross margins to 73%, a 27% reduction in operating loss, a 38% improvement in adjusted EBITDA loss, and importantly, a reduction in operating cash burn to $200,000 excluding restructuring payments. These gains reflect disciplined execution across our organization, including manufacturing optimization, improved working capital management, commercial execution, and tighter cost controls. As a result, we believe we remain on track toward our objective of achieving operating cash flow breakeven in the second half of this year.

Over the past couple of years, our priorities have been clear. We have needed to strengthen the financial foundation of the Company, improve commercial and operating execution, advance our regulatory programs, and position the business for sustainable long-term growth. During the second quarter, we continued making meaningful progress against each of these objectives. While we are not yet where we want to be, we believe CytoSorbents today is better positioned for success than it was a year ago.

Four Independent

Value Drivers

Looking ahead, we believe CytoSorbents has strong value creation opportunities. We believe we have four independent value drivers over the next six to eighteen months and that each has the potential to strengthen the business and create meaningful long-term shareholder value by reducing risk, expanding profitability, opening new markets, and unlocking strategic value.

First Value

Driver: Achieving Operating Cash Flow Breakeven

Our first value driver is reducing financial risk by achieving sustainable operating cash flow breakeven.

Over the past year, we have focused relentlessly on improving the economics of our business. Product gross margin improved to 73% during the second quarter through manufacturing optimization, improved sourcing, and production efficiencies. We also lowered our cash burn through improved commercial execution, collections, and working capital management while continuing to streamline our organization. Since September 2025, we have reduced our workforce by approximately 23%, creating a leaner and more focused company.

As a result, operating cash burn declined to approximately $200,000 during the quarter, excluding restructuring charges, representing another meaningful step toward operating cash flow breakeven.

We believe this milestone is important because it fundamentally changes the Company's financial profile. Every dollar of operating cash burn eliminated reduces future financing needs, strengthens our balance sheet, increases strategic flexibility, and allows a greater proportion of future growth to accrue to shareholders. Although important work remains, we believe the progress achieved over the past year demonstrates that this strategy is working."

Second Value

Driver: Returning the CytoSorb Business to Sustainable, Profitable Growth

Our second value driver is returning our core CytoSorb business to sustainable, profitable growth.

Although overall revenue growth remains modest today, the majority of the business did well during the second quarter, with 16% growth in distributor and strategic partner sales despite geopolitical disruption in the Middle East, and 9% growth in direct sales outside of Germany, but offset by a 24% decrease in Germany sales, attributed to a smaller, but more focused sales force following our restructuring. In Germany, we have significantly improved the efficiency of our smaller commercial organization and expect to drive a return to growth in the country by regaining full territory coverage through the addition of three to five new sales representatives through early 2027.

At the same time, our messaging and training of treating the “Right Patient, at the Right Time, with the Right Dose” continues to resonate with customers. This is partially evident in the increasing customer adoption of our PuriFi® pump platform and HotSwap® technology which have been received very well. These technologies simplify therapy delivery, encourage earlier and more intensive intervention, and promote more consistent utilization of CytoSorb.

We believe these and other initiatives, particularly the operational investments and commercial restructuring completed over the past year, have positioned us for greater sales effectiveness that can strengthen both clinical adoption and long-term profitable growth of the franchise.

Third Value

Driver: Opening the U.S. Market Through DrugSorb-ATR

Our third value driver is obtaining FDA marketing approval for DrugSorb-ATR and opening what we believe represents one of the Company's most important long-term growth opportunities.

DrugSorb-ATR addresses... (truncated)et need in cardiac surgery by removing commonly prescribed blood thinners during cardiopulmonary bypass for patients requiring urgent surgery. With the positive results of the STAR-T trial in CABG patients now published and the growing body of real-world evidence using our therapies for the anti-platelet drug Brilinta® and the direct oral anticoagulants, Eliquis® and Xarelto®, we are confident in the worldwide potential of our technologies for this application. In the U.S. and Canada alone, with future approval, we believe this represents an initial market opportunity of approximately $500 million to $1 billion, with the potential to expand substantially as additional surgical indications are pursued.

During August, we have two important FDA pre-submission meetings scheduled. The first is to discuss options to generate additional mechanistic data requested by FDA for our Brilinta® program. Following this meeting, we intend to finalize and confirm the testing protocol with FDA, which may require an additional meeting with the Agency. Once finalized, we anticipate completing the required testing, and submitting a new De Novo application in early 2027 that will include these data and new real-world clinical evidence analyses involving four times the number of coronary artery bypass graft (CABG) patients on Brilinta® treated with DrugSorb-ATR, compared to the original STAR-T trial.

In the second scheduled meeting, we will present our data to the FDA supporting a potential parallel De Novo submission for DrugSorb-ATR in patients receiving direct oral anticoagulants, or DOACs, and discuss what additional information, if any, the Agency believes is necessary.

We believe these meetings will provide additional clarity toward FDA marketing authorization. Successful marketing approval would establish a second commercial franchise alongside our international CytoSorb business, open access to the world's largest healthcare market, further validate our adsorption technology platform, increase our gross margins and potential profitability, and create opportunities for future expansion.

Fourth Value

Driver: Unlocking the Strategic Value of HemoDefend-BGA

Our fourth value driver is realizing the strategic value of HemoDefend-BGA - a technology that we believe is not fully reflected in today's valuation.

Developed with approximately $16 million of prior non-dilutive U.S. government funding, HemoDefend-BGA is a sophisticated blood filter designed to remove anti-A and anti-B antibodies from plasma and platelet products, enabling the production of ‘universal’ blood products that can be transfused regardless of recipient blood type - without electricity, capital equipment, or complex processing.

The technology has the potential to simplify blood inventories, reduce waste, lower costs, and improve access to life-saving blood products. Leading blood centers have helped to evaluate and validate the technology, and we believe its commercial potential extends well beyond today's blood banking model.

As one example, imagine the simplification and cost savings to hospital blood banks from currently maintaining 4 types of plasma (A, B, AB, O) and 4 types of platelets to now just 1 universal plasma and 1 universal platelet product. Or picture a future where every ambulance, first responder, or military vehicle around the world carries freeze-dried universal plasma on board - without refrigeration, without the need to blood type, and ready for immediate transfusion to patients suffering severe trauma and life-threatening hemorrhage. We believe HemoDefend-BGA has the potential to help make that future possible.

Over the past year, we completed product development, and in July 2026 we received constructive FDA feedback regarding our anticipated clinical pathway following a pre-submission interaction with the Agency. In addition, we continue to have encouraging discussions with U.S. government agencies regarding potential non-dilutive funding for future clinical development.

While our immediate priorities remain achieving operating cash flow breakeven, growing the CytoSorb franchise, and advancing DrugSorb-ATR, we believe HemoDefend-BGA represents a valuable strategic asset with multiple potential pathways to create shareholder value, including commercial partnerships, licensing opportunities, government funding, or other strategic alternatives.

Looking Ahead:

Four Independent Value Drivers. One Uncommon Value.

Taken together, these four value drivers represent multiple independent opportunities to create value over the next 6 to 18 months.

We believe each of these initiatives has the potential to independently strengthen our business and increase shareholder value. Together, they have the potential to fundamentally transform CytoSorbents into a stronger, more profitable, and more diversified medical technology company.

Dr. Chan concluded,

“Although more work remains, we believe our accomplishments over the past several quarters have stabilized the company and have positioned it for this next phase, where our entire organization remains intensely focused on disciplined execution. In the near future, we intend to regain compliance with our Nasdaq listing requirements, broaden the awareness of our Company and our four separate value drivers, and secure the Company financially. We appreciate our shareholder’s support and look forward to updating them as we continue to make progress on each of these important objectives.”

Second Quarter

2026 Earnings Conference Call

CytoSorbents’ management will host a live conference call, presentation webcast, and a question-and-answer session with the following information:

Date:

Thursday, August 6, 2026

Time:

4:30 PM ET

Live webcast link: https://app.webinar.net/v62381bx4na

It is recommended that participants join approximately 10 minutes prior to the start of the call.. archived recording of the conference call will be available under the Investor Relations section of the Company’s website at https://ir.cytosorbents.com/

About DrugSorb-ATR

In the U.S. and

Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two U.S. Food and Drug Administration (“FDA”) Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.

The Company continues to actively pursue regulatory approval of DrugSorb-ATR with the FDA and expects to pursue regulatory approval in Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.

About Non-GAAP

Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Share which excludes non-cash stock compensation expense, the gain or loss of foreign exchange translation, and restructuring charges from Net Loss and Net Loss Per Share, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons.

We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements. For a reconciliation of non-GAAP financial measures to the most comparable GAAP measure, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.

About CytoSorbents

Corporation (NASDAQ: CTSO)

CytoSorbents

Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents’ lead product,

CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under

CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United

States.

In the U.S. and Canada, CytoSorbents is... (truncated)an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two

FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™,

HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the Company’s website at h ttps://ir.cytosorbents.com/ or follow us on Facebook and X.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands, except share and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue, net9,6339,61718,49718,344
Cost of goods sold2,5842,8035,3185,323
Gross profit7,0496,81413,17913,021
Operating expensesResearch and development, net of grant income1,4531,2622,4782,924
Operating expensesSelling, general and administrative7,9649,16716,07317,599
Operating expensesRestructuring270310
Operating expensesTotal operating expenses9,68710,42918,86120,523
Operating expensesLoss from operations-2,638-3,615-5,682-7,502
Other income (expense)Interest expense, net-868-616-1,726-1,221
Other income (expense)Gain (loss) on foreign currency transactions-9116,178-2,1399,192
Other income (expense)Total other income (expense), net-1,7795,562-3,8657,971
Other income (expense)Net income (loss)-4,4171,947-9,547469
Other income (expense)Basic net income (loss) per common share-0.070.03-0.150.01
Other income (expense)Diluted net income (loss) per common share-0.070.03-0.150.01
Weighted Average Shares of Common Stock OutstandingBasic62,806,69462,608,59862,772,76161,675,447
Weighted Average Shares of Common Stock OutstandingDiluted62,806,69467,166,37762,772,76166,255,298
Other comprehensive income (loss):Foreign currency translation adjustment, net of tax1,105-5,4761,981-8,212
Other comprehensive income (loss):Comprehensive loss-3,312-3,529-7,566-7,743

Income Statement

Three Months Ended — RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES (in thousands)

Three Months Ended – June 30, – 2026 – (amounts, in thousands)Three Months Ended – June 30, – 2025 – (amounts, in thousands)Six Months Ended – June 30, – 2026 – (amounts, in thousands)Six Months Ended – June 30, – 2025 – (amounts, in thousands)
Net income (loss)-4,4171,947-9,547469
Depreciation and amortization expense351404699773
Income tax expense (benefit)$-$-$-$-
Interest expense (income)8686161,7261,221
EBITDA – non-GAAP measure-3,1982,967-7,1222,463
Non-cash stock-based compensation expense3685719121,391
(Gain)/Loss on foreign currency transactions911-6,1782,139-9,192
Restructuring270310
Adjusted EBITDA – non-GAAP measure-1,649-2,640-3,761-5,338
Net income (loss)-4,4171,947-9,547469
Non-cash stock-based compensation expense3685719121,391
(Gain)/Loss on foreign currency transactions911-6,1782,139-9,192
Restructuring270310
Adjusted net loss – non-GAAP measure-2,868-3,660-6,186-7,332
Weighted average common shares outstandingBasic62,806,69462,608,59862,772,76161,675,447
Weighted average common shares outstandingDiluted62,806,69467,166,37762,772,76166,255,298
Weighted average common shares outstandingBasic net income (loss) per common share-0.070.03-0.150.01
Weighted average common shares outstandingDiluted net income (loss) per common share-0.070.03-0.150.01
Weighted average common shares outstandingNon-cash stock-based compensation expense - basic0.010.010.010.02
Weighted average common shares outstandingNon-cash stock-based compensation expense - diluted0.010.010.010.02
Weighted average common shares outstanding(Gain)/Loss on foreign currency transactions - basic0.01-0.10.03-0.15
Weighted average common shares outstanding(Gain)/Loss on foreign currency transactions - diluted0.01-0.090.03-0.14
Weighted average common shares outstandingAdjusted net income (loss) per common share – basic – non-GAAP measure-0.05-0.06-0.1-0.12
Weighted average common shares outstandingAdjusted net income (loss) per common share – diluted – non-GAAP measure-0.05-0.05-0.1-0.11

Balance Sheet

December 31, — (in thousands, except share data)

June 30, – 2026 – (unaudited)December 31, – 2025
Current Assets:Cash and cash equivalents4,4136,249
Current Assets:Accounts receivable, net of allowances of $421 and $164 as of June 30, 2026 and December 31, 20256,7867,550
Current Assets:Inventories - net3,6865,281
Current Assets:Prepaid expenses and other current assets8521,554
Current Assets:Total current assets15,73720,634
Current Assets:Property and equipment - net7,1727,823
Current Assets:Restricted cash1,5221,522
Current Assets:Right-of-use asset10,61210,924
Current Assets:Patents - net2,8643,226
Current Assets:Other assets5353
Current Assets:Total assets37,96044,182
Current Liabilities:Accounts payable2,0022,869
Current Liabilities:Accrued expenses and other current liabilities7,2836,299
Current Liabilities:Lease liability – current portion589541
Current Liabilities:Current maturities of long-term debt, net of debt discount14,149
Current Liabilities:Total current liabilities24,0239,709
Current Liabilities:Lease liability, net of current portion11,59611,903
Current Liabilities:Long-term debt, net of current portion and debt discount3,09216,667
Current Liabilities:Total liabilities38,71138,279
Stockholders’ equity (deficit)Common Stock, par value $0.001, 100,000,000 shares authorized; 62,842,748 and 62,804,305 shares issued and outstanding as of June 30, 2026 and December 31, 2025 respectively6363
Stockholders’ equity (deficit)Additional paid-in capital321,936321,024

Cash Flow

(in thousands)

Six – Months Ended – June 30, – 2026Six – Months Ended – June 30, – 2025
Cash flows from operating activitiesNet income (loss)-9,547469
Adjustments to reconcile net income (loss) to net cash used in operating activities:Amortization of debt discount573381
Adjustments to reconcile net income (loss) to net cash used in operating activities:Amortization of patents123124
Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization576649
Adjustments to reconcile net income (loss) to net cash used in operating activities:Amortization of right-of-use asset5372
Adjustments to reconcile net income (loss) to net cash used in operating activities:Loss on abandoned patents338
Adjustments to reconcile net income (loss) to net cash used in operating activities:Write-off of inventory253
Adjustments to reconcile net income (loss) to net cash used in operating activities:Bad debt expense (recovery)2409
Adjustments to reconcile net income (loss) to net cash used in operating activities:Stock-based compensation9121,391
Adjustments to reconcile net income (loss) to net cash used in operating activities:Foreign currency transaction (gains) losses2,139-9,192
Changes in operating assets and liabilitiesAccounts receivable377257
Changes in operating assets and liabilitiesInventories1,512-925
Changes in operating assets and liabilitiesPrepaid expenses and other current assets6451,897
Changes in operating assets and liabilitiesOther assets1
Changes in operating assets and liabilitiesAccounts payable and accrued expenses313-360
Changes in operating assets and liabilitiesNet cash used in operating activities-1,745-4,975
Cash flows from investing activitiesPurchases of property and equipment-25-39
Cash flows from investing activitiesDisposals of property and equipment85
Cash flows from investing activitiesPayments for patent costs-99-140
Cash flows from investing activitiesNet cash used in investing activities-39-179
Cash flows from financing activitiesCash for exercise of warrants, net1,439
Cash flows from financing activitiesProceeds from rights offering, net5,392
Cash flows from financing activitiesNet cash provided by financing activities6,831
Cash flows from financing activitiesEffect of exchange rates on cash-52285
Cash flows from financing activitiesNet change in cash, cash equivalents, and restricted cash-1,8361,962
Cash flows from financing activitiesCash, cash equivalents, and restricted cash as of beginning of period7,7719,764
Cash flows from financing activitiesCash, cash equivalents, and restricted cash as of end of period5,93511,726
Supplemental disclosure of cash flow informationCash paid for interest1,2151,018
Supplemental disclosure of non-cash financing activitiesFair value of common stock warrants issued in connection with the rights offering$—556
Full release

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities

Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,”

“expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”

“potential,” “continue” and similar words, although some forward-looking statements are expressed differently.

You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to reduce costs, optimize operations, and achieve cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please

Click to Follow Us on

Facebook and

X

U.S. Company Contact:

Peter J. Mariani, Chief Financial Officer

305 College Road

East

Princeton, NJ 08540 ir@cytosorbents.com

CYTOSORBENTS

CORPORATION

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Cytosorbents earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.